Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets

CobenfyPositive

AI Analysis

Summary

Neurosterix raised $105 million in a Series B round to fund its lead schizophrenia candidate, which hits one of the targets of Bristol Myers Squibb's Cobenfy. The company is reuniting key figures behind Cobenfy.

Outcome Details

$105M Series B financing to fund lead schizophrenia candidate

Importance:5/10

Sentiment:

0.50

Series Bschizophreniaprivate financingCobenfyneuropsychiatry

Related Companies

$BMY

Read the original article

Published by Endpoints News on November 11, 2026 9:00 PM

Read Original